ADC: The Next Big Opportunity For Oncology Drugs

The commercial success of mAb products such as Rituxan, Erbitux, and Herceptin has catapulted mAbs to the forefront of molecular medicine.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news